Our personalized approach ensures you get the right treatment tailored to your needs
New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025
Effects of different selenium source on selenium distribution, loin quality and antioxidant status in finishing pigs
Think of it as supporting your bodys ongoing recovery and maintenance processes, not as a one-time fix
Both trials will assess once-weekly VK2735 over 78 weeks, with participants being randomly assigned to 7.5 mg, 12.5 mg or 17.5 mg of the study drug or placebo
now they will have to adapt to new shifts in obesity treatment